טוען...
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the potential for targeted therapeutics using small mole...
שמור ב:
| הוצא לאור ב: | Front Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6534082/ https://ncbi.nlm.nih.gov/pubmed/31165048 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00417 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|